Action of pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal polypeptide on the rat vascular system: effects on blood pressure and receptor binding

ABSTRACT The N-terminal fragment (PACAP 27) of the novel neuropeptide, pituitary adenylate cyclase-activating polypeptide 38 (PACAP 38), has 68% homology with vasoactive intestinal polypeptide (VIP). The administration of bolus doses of PACAP 38 and its 27 amino acid N-terminal fragment (PACAP 27) c...

Full description

Saved in:
Bibliographic Details
Published inJournal of endocrinology Vol. 129; no. 1; pp. 69 - 73
Main Authors NANDHA, K. A, BENITO-ORFILA, M. A, SMITH, D. M, GHATEI, M. A, BLOOM, S. R
Format Journal Article
LanguageEnglish
Published Colchester BioScientifica 01.04.1991
Portland Press
Subjects
Animals
Biological and medical sciences
Blood Pressure - drug effects
Blood Vessels - metabolism
Blood vessels and receptors
Cardiovascular System - drug effects
Cell Membrane - metabolism
Dose-Response Relationship, Drug
Female
Fundamental and applied biological sciences. Psychology
Neuropeptides - metabolism
Neuropeptides - pharmacology
Pituitary Adenylate Cyclase-Activating Polypeptide
Protein Binding
Rats
Rats, Inbred Strains
Vasoactive Intestinal Peptide - metabolism
Vasoactive Intestinal Peptide - pharmacology
Vertebrates: cardiovascular system
Vertebrata
Mammalia
Radioreceptor assay
Rat
Blood vessel
Rodentia
Circulatory system
Hemodynamics
VIP
Neuropeptide
Biological receptor
Online AccessGet full text

Cover

More Information
Summary:ABSTRACT The N-terminal fragment (PACAP 27) of the novel neuropeptide, pituitary adenylate cyclase-activating polypeptide 38 (PACAP 38), has 68% homology with vasoactive intestinal polypeptide (VIP). The administration of bolus doses of PACAP 38 and its 27 amino acid N-terminal fragment (PACAP 27) caused a rapid but transient dose-dependent hypotensive effect in the anaesthetized rat. The amplitude and duration of the response obtained by PACAP 38 was comparable with VIP whereas PACAP 27 was three times less potent than VIP. Furthermore, radioreceptor binding studies demonstrated that 125I-labelled PACAP 27 and 125I-labelled VIP bound to membranes prepared from blood vessels. Both PACAP 27 and VIP were capable of displacing the other from these binding sites. We propose that the hypotensive effect is via the same receptor type. Journal of Endocrinology (1991) 129, 69–73
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0022-0795
1479-6805
DOI:10.1677/joe.0.1290069